Share ownership Biogen Inc.

BIIB

US09062X1037

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-08 pm EST			5-day change	1st Jan Change
180.44 ^USD	-0.47%		+1.50%	+18.00%

Dec. 05	Stoke Therapeutics, Inc. and Biogen Inc. Present Data That Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome	CI
Dec. 05	Stoke Therapeutics and Biogen present data that further support the disease-modifying potential of zorevunersen	RE

Share class: Biogen Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	170,174,937	145,495,299 ( 85.5 %)	23,800,000 ( 13.99 %)	85.5 %

Major shareholders: Biogen Inc.

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 11.79 %	17,289,235	11.79 %	3 148 M $
PRIMECAP Management Co. 10.19 %	14,954,697	10.19 %	2 723 M $
BlackRock Advisors LLC 6.945 %	10,188,789	6.945 %	1 855 M $
STATE STREET CORPORATION 4.99 %	7,319,749	4.99 %	1 333 M $
Wellington Trust Co., NA 2.895 %	4,246,504	2.895 %	773 M $
BlackRock Life Ltd. 2.888 %	4,237,235	2.888 %	772 M $
Geode Capital Management LLC 2.773 %	4,068,781	2.773 %	741 M $
Point72 Asset Management LP 2.64 %	3,872,901	2.64 %	705 M $
Invesco Advisers, Inc. 1.653 %	2,424,262	1.653 %	441 M $
Norges Bank (13F) 1.543 %	2,264,177	1.543 %	412 M $
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	76.12%
Other	9.73%
State Street Corp.	4.99%
Schweizerische Nationalbank	0.29%
Sumitomo Mitsui Trust Group, Inc.	0.28%
Individuals	0.18%
Swedbank AB	0.16%
Governments	0.16%
Banco Bilbao Vizcaya Argentaria SA	0.09%
Manulife Financial Corp.	0.08%
SEI Investments Co.	0.06%
Baader Bank AG	0.04%
Danske Bank A/S	0.03%
The Bank of Nova Scotia	0.02%
Skandinaviska Enskilda Banken AB	0.02%
Meitav Investment House Ltd.	0.02%
Banque Cantonale Vaudoise	0.01%
Fifth Third Bancorp	0.01%
Unknown	7.71%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	70.38%
United Kingdom	9.71%
Canada	2.44%
Norway	1.77%
Switzerland	1.23%
Australia	1.14%
France	0.92%
Japan	0.87%
Netherlands	0.58%
Sweden	0.57%
Hong Kong	0.36%
Germany	0.33%
Spain	0.29%
Ireland	0.27%
South Korea	0.24%
Luxembourg	0.18%
Individuals	0.18%
Denmark	0.15%
China	0.12%
Finland	0.1%
Israel	0.09%
Italy	0.07%
Singapore	0.06%
Czech Republic	0.05%
Austria	0.04%
Slovenia	0.03%
Belgium	0.02%
India	0.02%
South Africa	0.02%
New Zealand	0.02%
Taiwan	0.01%
Cayman Islands	0.01%
Liechtenstein	0.01%
Mexico	0.01%

Based on 1000 largest holdings

Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (74.6%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (6.7%) ; - other (18.7%): primarily revenues from partnership agreements.

Employees

7,605

Sector

Pharmaceuticals

Calendar

Jan. 28 - Q4 2025 Earnings Release (Projected)

More about the company